Heze Pharmaceutical Secures Strategic Investment from YF Capital

According to news.yaozh.com, recently, Hangzhou Heze Pharmaceutical Technology Co., Ltd. ("Heze Pharma") has closed a strategic investment from YF Capital. With the entry of new capital, Heze Pharma will continue to enhance the strength of R&D as the basis, and build an ecosystem with the MAH (Marketing Authorization Holder) whole industry chain.

Founded in 2006, Heze Pharma is a national high-tech enterprise located in Hangzhou Economic&Technology Development Zone with about 200 excellent staff specialized in drug R&D. The drug R&D standard lab is about 7000m2 well-equipped with equipment worth more than 80 million yuan. 

Since 2020, Heze Pharma has been continuously exploring its layout in terms of consolidating its core business, upgrading the MAH whole-industry-chain service, and promoting the MAH platform construction, etc. The company has made remarkable achievements.

Heze Pharma strives to build leading R&D platforms for slow drug release, chemical modification of peptide, special injections, and inhalation preparations, so as to form a technical "moat". It carries on technological innovation, reasonable layout in the development of generic drugs and innovative drugs, and is currently developing a number of improved drugs and a series of multi-target peptide drugs.

Viewing MAH and CSO as opportunities to drive its rich experience in drug quality management and dozens of generic drugs' R&D as advantages, Heze Pharma will endeavor to be a top enterprise in putting MAH into practice, expand the sales-related field, dock international novel pharmaceutical technology and connect the whole industry chain. 

Founded in 2010, YF Capital is a leading private equity firm in China. YF Capital currently manages multiple USD and RMB funds. The company has formed deep sector expertise and industry insights in our focused sectors, including internet, technology, healthcare, entertainment, consumer, finance and logistics.